{
  "nctId": "NCT02822794",
  "briefTitle": "Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Participants With Chronic Genotype 1 or 2 Hepatitis C Virus Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen",
  "officialTitle": "A Phase 3, Multicenter, Randomized, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 or 24 Weeks in Subjects With Chronic Genotype 1 or 2 HCV Infection Who Have Previously Failed a Direct-Acting Antiviral-Containing Regimen",
  "protocolDocument": {
    "nctId": "NCT02822794",
    "filename": "Prot_001.pdf",
    "label": "Study Protocol",
    "date": "2016-06-13",
    "uploadDate": "2018-06-22T13:54",
    "size": 3094776,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT02822794/document/Prot_001.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE3"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 117,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2016-07-25",
    "completionDate": "2017-08-25",
    "primaryCompletionDate": "2017-06-02",
    "firstSubmitDate": "2016-06-30",
    "firstPostDate": "2016-07-04"
  },
  "eligibilityCriteria": {
    "criteria": "Key Inclusion Criteria:\n\n* Genotype 1 or 2 HCV infection\n* Chronic HCV infection (≥ 6 months prior to screening) documented by prior medical history or liver biopsy\n* Previously treated with a DAA-containing regimen of at least 4 week duration\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "20 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)",
        "description": "SVR12 was defined as HCV RNA \\< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.",
        "timeFrame": "Posttreatment Week 12"
      },
      {
        "measure": "Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event",
        "timeFrame": "Up to 24 weeks"
      }
    ],
    "secondary": [
      {
        "measure": "Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)",
        "description": "SVR4 was defined as HCV RNA \\< LLOQ at 4 weeks after stopping study treatment.",
        "timeFrame": "Posttreatment Week 4"
      },
      {
        "measure": "Percentage of Participants With SVR at 24 Weeks After Discontinuation of Therapy (SVR24)",
        "description": "SVR 24 was defined as HCV RNA \\< LLOQ at 24 weeks after stopping study treatment.",
        "timeFrame": "Posttreatment Week 24"
      },
      {
        "measure": "Percentage of Participants With HCV RNA < LLOQ at Week 1",
        "timeFrame": "Week 1"
      },
      {
        "measure": "Percentage of Participants With HCV RNA < LLOQ at Week 2",
        "timeFrame": "Week 2"
      },
      {
        "measure": "Percentage of Participants With HCV RNA < LLOQ at Week 3",
        "timeFrame": "Week 3"
      },
      {
        "measure": "Percentage of Participants With HCV RNA < LLOQ at Week 4",
        "timeFrame": "Week 4"
      },
      {
        "measure": "Percentage of Participants With HCV RNA < LLOQ at Week 5",
        "timeFrame": "Week 5"
      },
      {
        "measure": "Percentage of Participants With HCV RNA < LLOQ at Week 6",
        "timeFrame": "Week 6"
      },
      {
        "measure": "Percentage of Participants With HCV RNA < LLOQ at Week 8",
        "timeFrame": "Week 8"
      },
      {
        "measure": "Percentage of Participants With HCV RNA < LLOQ at Week 10",
        "timeFrame": "Week 10"
      },
      {
        "measure": "Percentage of Participants With HCV RNA < LLOQ at Week 12",
        "timeFrame": "Week 12"
      },
      {
        "measure": "Percentage of Participants With HCV RNA < LLOQ at Week 16",
        "timeFrame": "Week 16"
      },
      {
        "measure": "Percentage of Participants With HCV RNA < LLOQ at Week 20",
        "timeFrame": "Week 20"
      },
      {
        "measure": "Percentage of Participants With HCV RNA < LLOQ at Week 24",
        "timeFrame": "Week 24"
      },
      {
        "measure": "Change From Baseline in HCV RNA at Week 1",
        "timeFrame": "Baseline; Week 1"
      },
      {
        "measure": "Change From Baseline in HCV RNA at Week 2",
        "timeFrame": "Baseline; Week 2"
      },
      {
        "measure": "Change From Baseline in HCV RNA at Week 3",
        "timeFrame": "Baseline; Week 3"
      },
      {
        "measure": "Change From Baseline in HCV RNA at Week 4",
        "timeFrame": "Baseline; Week 4"
      },
      {
        "measure": "Change From Baseline in HCV RNA at Week 5",
        "timeFrame": "Baseline; Week 5"
      },
      {
        "measure": "Change From Baseline in HCV RNA at Week 6",
        "timeFrame": "Baseline; Week 6"
      },
      {
        "measure": "Change From Baseline in HCV RNA at Week 8",
        "timeFrame": "Baseline; Week 8"
      },
      {
        "measure": "Change From Baseline in HCV RNA at Week 10",
        "timeFrame": "Baseline; Week 10"
      },
      {
        "measure": "Change From Baseline in HCV RNA at Week 12",
        "timeFrame": "Baseline; Week 12"
      },
      {
        "measure": "Change From Baseline in HCV RNA at Week 16",
        "timeFrame": "Baseline; Week 16"
      },
      {
        "measure": "Change From Baseline in HCV RNA at Week 20",
        "timeFrame": "Baseline; Week 20"
      },
      {
        "measure": "Change From Baseline in HCV RNA at Week 24",
        "timeFrame": "Baseline; Week 24"
      },
      {
        "measure": "Percentage of Participants With Overall Virologic Failure",
        "description": "Virologic failure was defined as:\n\n* On-treatment virologic failure:\n\n  * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \\< LLOQ while on treatment), or\n  * Rebound (confirmed \\> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or\n  * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment)\n* Virologic relapse:\n\n  * Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \\< LLOQ at last on-treatment visit.",
        "timeFrame": "Up to Posttreatment Week 24"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 0,
      "totalCount": 1
    },
    "endpoints": {
      "primaryCount": 2,
      "secondaryCount": 27,
      "otherCount": 0,
      "totalCount": 29
    },
    "studyDesign": {
      "phases": [
        "PHASE3"
      ],
      "isRandomized": true,
      "isMasked": false,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:30:23.531Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}